Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANE-Uganda: Sildenafil for Birth Asphyxia in Africa
NCT05275725Phase 1Completed
- Start
- Jul 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sildenafil in birth asphyxia and neonatal encephalopathy (NE). Primary endpoint: Maximum tolerable dose at 30 days. Started Jul 2022; status: completed.
02
Drugs
sildenafil
03
Conditions
birth asphyxianeonatal encephalopathy (NE)
Beyond the preview
Go deeper on NCT05275725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275725.